FCARH143 is a BCMA targeted CAR T Cell therapy being developed at the Fred Hutchinson Cancer Research Center in collaboration with Juno Therapeutics and the National Cancer Institute.

SparkCures ID 336
Generic Name FCARH143
Additional Names Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes
Treatment Classifications
Treatment Targets

Clinical Trials


There are no resources, links or videos to display for this treatment.